Change in Motor and Nonmotor Symptoms Severity in a “Real-Life” Cohort of Subjects with Parkinson’s Disease

Table 1

Comparison of drug treatment between initial and follow-up visits.

	Initial visit	Follow-up	value
Use of levodopa	40 (75.5%)	45 (84.9%)	0.063
Levodopa dose (mg)	447.8 ± 399.6	487.5 ± 348.8	0.419
Use of dopamine agonists	31 (41.5%)	28 (52.8%)	0.181
Use of MAOi	4 (7.5%)	8 (15.7%)	0.133
DA-LEDD (mg)	88.2 ± 130.3	160.3 ± 186	0.009
Total LEDD	556.8 ± 410.4	676.3 ± 380.5	0.015
Use of antidepressants	12 (22.6%)	13 (24.5%)	>0.99
Surgery (bilateral DBS)	0%	2 (3.8%)	—

Total (percentage). Mean ± standard deviation. LEDD: levodopa equivalent daily dose. DA-LEDD: dopamine agonists-levodopa equivalent daily dose. MAOi: monoamine oxidase inhibitor. DBS: deep brain stimulation.